InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod

STOCKHOLM, Aug. 24, 2021 -- (Healthcare Sales & Marketing Network) -- InDex Pharmaceuticals Holding AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III clinical study CONCLUDE in the United... Biopharmaceuticals, Gastroenterology, FDA InDex Pharmaceuticals, cobitolimod, ulcerative colitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news